CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...
* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...
CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced?that its partner, Windward Bio AG ("Windward Bio") has launched?its Phase 2 POLARIS clinical study, assessing long-acting dosing of?SKB37...
CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰萊?)?in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰萊? )?was...
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...
CHENGDU, China, June 7, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated ...
CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of t...
CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six cl...
CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotec...
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 30 to June 3. Resu...
CHENGDU, China, April 21, 2025 /PRNewswire/ --?Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment o...
Notable Progress in R&D and Commercialization Gross Profit Surging 68% FINANCIAL HIGHLIGHTS ? Revenue?was approximately RMB1,933.0 million, representing a year-on-year increase of 25.5%. ? Gross profit was approximately RMB1,273.7 million, representing a year-on-year increase of 67.8%. ? Res...
CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-00...
CHENGDU, China, March 10, 2025 /PRNewswire/ --?Sichuan?Kelun-Biotech?Biopharmaceutical?Co., Ltd. (the?"Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held inSan Francisco, USA, from Feb. 13-15, 2025,?Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and safety ...
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ --?Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovativ...
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited? ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...
CHENGDU, China, Nov. 27, 2024 /PRNewswire/ --?Sichuan?Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically?developed?trophoblast cell-surface an...
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal?phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan?Kelun-Biotech Biopharmaceutical Co., L...